USING THE DRUG ESMOLOL, A FAST ACTING, WATER-SOLUBLE BETA-1 ADRENERGIC BLOCKING AGENT, IT IS POSSIBLE TO CONTROL TACHYCARDIA IN PATIENTS DURING GENERAL ANESTHESIA AND POST-OPERATIVE.

USING THE DRUG ESMOLOL, A FAST ACTING, WATER-SOLUBLE BETA-1 ADRENERGIC BLOCKING AGENT, IT IS POSSIBLE TO CONTROL TACHYCARDIA IN PATIENTS DURING GENERAL ANESTHESIA AND POST-OPERATIVE.Y. THE GOAL OF THE PHASE I RESEARCH IS TO GENERATE A CLOSED-LOOP SYSTEM TO CONTROL TACHYCARDIA USING ESMOLOL. THE DESIGN WOULD BE ACCOMPLISHED USING AVAILABLE DIGITAL DESIGN TOOLS. THE ULTIMATE AIM IS TO MESH THE HEART RATE CONTROL SYSTEM WHICH WOULD RESULT FROM THIS EFFORT WITH ESTABLISHED METHODS FOR PHARMACOLOGIC CONTROL OF BLOOD-PRESSURE IN PATIENTS UNDER GENERAL ANESTHESIA AND IN POST-OPERATIVE PERIOD. THE SYNERGISTIC RESULT WOULD BE A MULTI-INPUT MULTI-OUTPUT CONTROL SYSTEM WHERIN TWO COMBINED CONTROLLERS WOULD WORK IN CONCERT TO ACHIEVE THE DESIRED CONTROL. PHASE I RESEARCH WOULD REQUIRE THE USE OF DOGS WHICH WOULD BE INFUSED WITH BOLUS DOSES OF ESMOLOL TO PRODUCE THE TIME-RESPONSE DATA REQUIRED TO OBTAIN A PLANT DESCRIPTION. A MATHEMATICAL MODEL WOULD THEN BE DEFINED AND A SIMULATION COMPOSED. USING ESTABLISHED SYSTEM ANALYSIS AND COMPENSATOR DESIGN TECHNIQUES, THE DESIRED CONTROLLER MAY BE EASILY DESIGNED AND TESTED WITH THE SIMULATION. MICROCOMPUTER CODE WOULD BE GENERATED DURING PHASE II INVOLVING TESTING OF THE CONTROL ALGORITHM ON ANIMAL AND HUMAN SUBJECTS. PHASE III INTEREST IN THE WORK HAS BEEN MANIFESTED BY THE DEVELOPERS OF THE DRUG AS WELL AS MANUFACTURERS OF MONITORING, COMPUTER, AND INFUSION PUMP EQUIPMENT.